MDM2 and ovarian carcinoma: The promising results showing activity of MDM2-p53 antagonists against wild-type TP53 ovarian cancer cell lines [16, 27] have prompted this investigation of combination treatment with rucaparib and Nutlin-3/RG7388 in a panel of wild-type TP53 ovarian cancer cell lines.